PMID- 32303862
OWN - NLM
STAT- MEDLINE
DCOM- 20200916
LR  - 20201211
IS  - 1862-3514 (Electronic)
IS  - 1862-3522 (Print)
VI  - 15
IP  - 1
DP  - 2020 Apr 17
TI  - Adherence to and persistence with zoledronic acid treatment for 
      osteoporosis-reasons for early discontinuation.
PG  - 58
LID - 10.1007/s11657-020-00733-4 [doi]
LID - 58
AB  - This retrospective study reports 81% long-term (> 3 years) adherence to and 77% 
      persistence with zoledronic acid (ZA) treatment in osteoporosis patients, with ZA 
      being costfree for patients. Eight percent of patients discontinued treatment 
      because of adverse events (AEs), with a tendency of higher discontinuation rate 
      in older patients. PURPOSE: This study investigated (1) long-term adherence to 
      and persistence with ZA treatment in a real-world setting, (2) extent to which an 
      adverse reaction to ZA impacted on adherence and persistence, and (3) whether 
      there were sex or age differences in patients that had early treatment 
      termination (ETT) due to AEs and those who adhered to the regimen. METHODS: All 
      patients treated with ZA at the Endocrinology Department at Linkoping University 
      Hospital, Linkoping, Sweden between 2012 and 2017 were included. ETT was defined 
      as < 3 ZA infusions, which was confirmed from patients' medical records. RESULTS: 
      A total of 414 patients were treated with ZA, with 81% receiving > 3 ZA 
      infusions. Three-year persistence was 77% for a treatment window of 
      365 days +/- 90 days (75% with 365 days +/- 60 days window). The most common reason 
      for ETT was AEs (8%), followed by medical conditions (5%), biological aging (3%), 
      and other (e.g., lost to follow-up [3%]). Most patients who discontinued 
      treatment because of AEs reported symptoms of acute-phase reaction, and tended to 
      be older than those who adhered to treatment (74 +/- 9 vs 70 +/- 13 years, 
      p = 0.064). There was no difference in sex ratio between the 2 groups (85% vs 90% 
      females, p = 0.367). CONCLUSION: Rates of long-term adherence to and persistence 
      with ZA treatment were high with a pre-scheduled 3-year treatment regimen in the 
      tax-financed Swedish healthcare system. AEs-mainly acute-phase reaction-were the 
      most common reason for ETT, occurring in nearly 1 out of 10 patients.
FAU - Spangeus, Anna
AU  - Spangeus A
AUID- ORCID: 0000-0002-7130-9158
AD  - Department of Acute Internal Medicine and Geriatrics, Linkoping University 
      Hospital, Linkoping, Sweden. anna.spangeus@liu.se.
AD  - Division of Diagnostics and Specialist Medicine, Department of Health, Medicine 
      and Caring Sciences, Linkoping University, Linkoping, Sweden. 
      anna.spangeus@liu.se.
FAU - Johansson, Simon
AU  - Johansson S
AD  - Division of Diagnostics and Specialist Medicine, Department of Health, Medicine 
      and Caring Sciences, Linkoping University, Linkoping, Sweden.
FAU - Woisetschlager, Mischa
AU  - Woisetschlager M
AUID- ORCID: 0000-0003-0066-4985
AD  - Division of Diagnostics and Specialist Medicine, Department of Health, Medicine 
      and Caring Sciences, Linkoping University, Linkoping, Sweden.
AD  - Department of Radiology, Linkoping University Hospital, Linkoping, Sweden.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20200417
PL  - England
TA  - Arch Osteoporos
JT  - Archives of osteoporosis
JID - 101318988
RN  - 0 (Bone Density Conservation Agents)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Aged
MH  - Bone Density Conservation Agents/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Medication Adherence/*statistics & numerical data
MH  - Middle Aged
MH  - Osteoporosis/*drug therapy
MH  - Retrospective Studies
MH  - Sweden
MH  - Time Factors
MH  - Withholding Treatment/*statistics & numerical data
MH  - Zoledronic Acid/*administration & dosage/adverse effects
PMC - PMC7165128
OTO - NOTNLM
OT  - Adherence
OT  - Adverse event
OT  - Bisphosphonate
OT  - Discontinuation
OT  - Osteoporosis
OT  - Zoledronic acid
COIS- Anna Spangeus has received lecture fees from Amgen Inc., Renapharma, and Mylan. 
      Simon Johansson and Mischa Woisetschlager declare that they have no conflict of 
      interest.
EDAT- 2020/04/19 06:00
MHDA- 2020/09/17 06:00
PMCR- 2020/04/17
CRDT- 2020/04/19 06:00
PHST- 2020/02/24 00:00 [received]
PHST- 2020/04/07 00:00 [accepted]
PHST- 2020/04/19 06:00 [entrez]
PHST- 2020/04/19 06:00 [pubmed]
PHST- 2020/09/17 06:00 [medline]
PHST- 2020/04/17 00:00 [pmc-release]
AID - 10.1007/s11657-020-00733-4 [pii]
AID - 733 [pii]
AID - 10.1007/s11657-020-00733-4 [doi]
PST - epublish
SO  - Arch Osteoporos. 2020 Apr 17;15(1):58. doi: 10.1007/s11657-020-00733-4.